1. Home
  2. DBVT vs PLBC Comparison

DBVT vs PLBC Comparison

Compare DBVT & PLBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DBVT
  • PLBC
  • Stock Information
  • Founded
  • DBVT 2002
  • PLBC 1980
  • Country
  • DBVT France
  • PLBC United States
  • Employees
  • DBVT N/A
  • PLBC N/A
  • Industry
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • PLBC Finance Companies
  • Sector
  • DBVT Health Care
  • PLBC Finance
  • Exchange
  • DBVT Nasdaq
  • PLBC Nasdaq
  • Market Cap
  • DBVT 239.9M
  • PLBC 236.7M
  • IPO Year
  • DBVT N/A
  • PLBC 2005
  • Fundamental
  • Price
  • DBVT $8.01
  • PLBC $42.73
  • Analyst Decision
  • DBVT Buy
  • PLBC Buy
  • Analyst Count
  • DBVT 4
  • PLBC 3
  • Target Price
  • DBVT $14.81
  • PLBC $57.67
  • AVG Volume (30 Days)
  • DBVT 102.2K
  • PLBC 12.1K
  • Earning Date
  • DBVT 07-29-2025
  • PLBC 07-16-2025
  • Dividend Yield
  • DBVT N/A
  • PLBC 2.76%
  • EPS Growth
  • DBVT N/A
  • PLBC 3.33
  • EPS
  • DBVT N/A
  • PLBC 4.95
  • Revenue
  • DBVT $3,497,000.00
  • PLBC $84,001,000.00
  • Revenue This Year
  • DBVT $1,700.53
  • PLBC $19.95
  • Revenue Next Year
  • DBVT $535.67
  • PLBC $22.19
  • P/E Ratio
  • DBVT N/A
  • PLBC $8.80
  • Revenue Growth
  • DBVT N/A
  • PLBC 9.14
  • 52 Week Low
  • DBVT $2.21
  • PLBC $32.50
  • 52 Week High
  • DBVT $12.78
  • PLBC $51.33
  • Technical
  • Relative Strength Index (RSI)
  • DBVT 41.18
  • PLBC 48.47
  • Support Level
  • DBVT $8.33
  • PLBC $43.05
  • Resistance Level
  • DBVT $9.92
  • PLBC $44.84
  • Average True Range (ATR)
  • DBVT 0.86
  • PLBC 1.10
  • MACD
  • DBVT -0.34
  • PLBC -0.22
  • Stochastic Oscillator
  • DBVT 1.48
  • PLBC 13.45

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

About PLBC Plumas Bancorp

Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.

Share on Social Networks: